AnaptysBio, Inc. $ANAB Stock Holdings Decreased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd decreased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 31.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,701 shares of the biotechnology company’s stock after selling 10,400 shares during the period. Y Intercept Hong Kong Ltd owned about 0.08% of AnaptysBio worth $1,259,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Los Angeles Capital Management LLC raised its stake in AnaptysBio by 1.5% during the fourth quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after buying an additional 225 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of AnaptysBio by 24.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 263 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of AnaptysBio by 21.2% in the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in shares of AnaptysBio by 1.4% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock valued at $1,743,000 after acquiring an additional 500 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter.

AnaptysBio Stock Performance

Shares of AnaptysBio stock traded down $0.20 during trading on Friday, hitting $66.39. 400,964 shares of the stock were exchanged, compared to its average volume of 628,133. AnaptysBio, Inc. has a 12 month low of $11.40 and a 12 month high of $72.36. The stock’s fifty day moving average is $60.27 and its 200 day moving average is $56.95. The stock has a market cap of $1.97 billion, a PE ratio of -61.47 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($1.20). The business had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. Sell-side analysts anticipate that AnaptysBio, Inc. will post -1.35 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a stock repurchase plan on Friday, March 27th that allows the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization allows the biotechnology company to buy up to 5,352,316.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

ANAB has been the subject of several recent research reports. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Barclays boosted their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a report on Friday, May 15th. Wall Street Zen downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, HC Wainwright assumed coverage on AnaptysBio in a report on Wednesday, June 10th. They set a “buy” rating and a $95.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.82.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.